Goblirsch Matthew, Richtig Georg, Slaby Ondrej, Berindan-Neagoe Ioana, Gerger Armin, Pichler Martin
College of Science, Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Institute of Experimental & Clinical Pharmacology, Medical University of Graz, 8010 Graz, Austria.
Pharmacogenomics. 2017 Jul;18(10):1027-1038. doi: 10.2217/pgs-2017-0004. Epub 2017 Jun 22.
Colorectal cancer is a common type of malignant disease with high rates of morbidity and mortality. Although treatment options have been expanded over the last years, the mainstay of curative treatment remains surgical removal of the tumor-bearing organ. Systemic treatment options include classic cytotoxic drugs as well as some biological agents. Noncoding RNAs are an evolving field in cancer diagnosis, prognosis and possible treatment. Noncoding miRNAs are small molecules with huge impact on gene expression. They have been a substantial part of cancer research for more than a decade. In this review article, the current knowledge of miRNAs and colorectal cancer diagnosis, prognosis and novel or evolving therapeutic concepts are discussed. Examples of how miRNAs might change the management of the disease will be described.
结直肠癌是一种常见的恶性疾病,发病率和死亡率都很高。尽管在过去几年中治疗选择有所增加,但根治性治疗的主要手段仍然是手术切除肿瘤所在器官。全身治疗选择包括经典的细胞毒性药物以及一些生物制剂。非编码RNA是癌症诊断、预后及可能治疗方面一个不断发展的领域。非编码微小RNA(miRNA)是对基因表达有巨大影响的小分子。十多年来,它们一直是癌症研究的重要组成部分。在这篇综述文章中,讨论了关于miRNA与结直肠癌诊断、预后以及新的或不断发展的治疗概念的当前知识。将描述miRNA可能如何改变该疾病治疗方式的实例。